Pharmacogenetics

CYP450 Enzyme Polymorphisms and Drug Metabolism

Investigation of cytochrome P450 genetic variants affecting individual drug metabolic capacity and clinical outcomes across populations.

RESEARCH GAP FRONTIERS

HLA Allele Associations with Adverse Drug Reactions

Study of human leukocyte antigen polymorphisms predicting severe immunogenic drug toxicities including Stevens-Johnson syndrome and toxic epidermal necrolysis.

RESEARCH GAP FRONTIERS

Warfarin Pharmacogenetics and Anticoagulation Management

Analysis of VKORC1 and CYP2C9 variants guiding personalized warfarin dosing to optimize anticoagulation control and minimize bleeding complications.

RESEARCH GAP FRONTIERS

Thiopurine Methyltransferase Deficiency Screening

Evaluation of TPMT genetic variants enabling pretreatment identification of patients at risk for azathioprine and 6-mercaptopurine toxicity.

RESEARCH GAP FRONTIERS

Clopidogrel Responsiveness and CYP2C19 Loss-of-Function

Assessment of CYP2C19 polymorphisms determining clopidogrel activation and predicting cardiovascular outcomes in antiplatelet therapy.

RESEARCH GAP FRONTIERS

Statins Pharmacogenomics and Myopathy Risk Prediction

Investigation of SLCO1B1 and other transporter variants predicting statin-induced muscle injury and lipid-lowering response variability.

RESEARCH GAP FRONTIERS

TPMT and NUDT15 Variants in Leukemia Treatment

Characterization of thiopurine metabolism genes optimizing 6-mercaptopurine and azathioprine dosing in pediatric acute lymphoblastic leukemia.

RESEARCH GAP FRONTIERS

Acetylator Phenotype and Isoniazid Hepatotoxicity

Study of NAT2 gene polymorphisms determining acetylation capacity and predicting tuberculosis drug-induced liver injury susceptibility.

RESEARCH GAP FRONTIERS

DPYD Deficiency and Fluoropyrimidine Chemotoxicity

Identification of dihydropyrimidine dehydrogenase variants preventing life-threatening 5-fluorouracil and capecitabine adverse events in cancer patients.

Abacavir Hypersensitivity and HLA-B*5701 Screening

Assessment of HLA-B*5701 allele association with abacavir-induced severe hypersensitivity reactions in HIV-positive populations.

Allopurinol Severe Cutaneous Adverse Reactions Genetics

Investigation of HLA-B*5801 and other genetic markers predicting allopurinol-induced Stevens-Johnson syndrome in gout patients.

Carbamazepine and Phenytoin Hypersensitivity HLA Variants

Study of HLA-A*3101 and HLA-B*1502 associations with severe cutaneous reactions to aromatic antiepileptic drugs.

Codeine Metabolism and CYP2D6 Ultra-Rapid Metabolizers

Evaluation of CYP2D6 gene duplications causing toxic morphine accumulation and adverse effects in codeine-treated patients.

Metoprolol Response and CYP2D6 Polymorphisms

Analysis of CYP2D6 variants determining beta-blocker efficacy and dose requirements for hypertension and cardiovascular disease management.

Tacrolimus Bioavailability and CYP3A5 Genotyping

Investigation of CYP3A5 expression variants guiding personalized tacrolimus dosing in transplant recipients for optimal immunosuppression.

Voriconazole Pharmacokinetics and CYP2C19 Variants

Study of CYP2C19 polymorphisms predicting voriconazole exposure variability and therapeutic drug monitoring needs in fungal infections.

SLCO1B1 Polymorphisms and Statin Drug Transporter

Examination of organic anion transporter protein variants affecting hepatic statin uptake and myopathy susceptibility risk.

Metformin Nephrotoxicity and OCT1 Transporter Variants

Investigation of organic cation transporter polymorphisms influencing metformin renal clearance and lactic acidosis risk in diabetic patients.

Dihydrofolate Reductase Inhibitors and MTHFR Polymorphisms

Study of methylenetetrahydrofolate reductase variants affecting methotrexate metabolism and toxicity in cancer and autoimmune disease treatment.

Methyltransferase Gene Variants and Drug Efficacy Prediction

Characterization of COMT and other methyltransferase polymorphisms predicting antipsychotic drug response and adverse effect susceptibility.

Epigenetic Modifications in Drug Response Heterogeneity

Investigation of DNA methylation and histone modifications regulating pharmacogene expression and inter-individual drug response variation.

MicroRNA Regulation of Pharmacogene Expression Networks

Study of miRNA-mediated post-transcriptional control of drug-metabolizing enzymes and transporters affecting pharmacological phenotypes.

Copy Number Variations in CYP2D6 Gene Locus

Characterization of CYP2D6 deletions, duplications, and hybrid genes creating poor, intermediate, extensive, and ultra-rapid metabolizer phenotypes.

Structural Variants and Drug Metabolism Gene Deletions

Investigation of large genomic rearrangements in pharmacogenes causing complete gene loss and altered drug bioavailability.

Genome-Wide Association Studies for Drug Response Traits

Large-scale discovery of common genetic variants associated with inter-individual variability in medication efficacy and safety outcomes.

Whole Exome Sequencing and Rare Pharmacogenetic Variants

Identification of novel rare coding variants in pharmacogenes with potential functional consequences for drug metabolism and response.

Ancestry-Specific Pharmacogenetic Variant Frequencies

Analysis of genetic variation in drug-metabolizing enzymes across diverse ancestral populations and implications for precision dosing.

Pharmacogenetics in Underrepresented Racial and Ethnic Groups

Investigation of pharmacogenetic differences among African, Hispanic, Asian, and Native American populations to improve equitable drug therapy.

Genotype-Phenotype Correlation in Metabolizer Classification

Establishment of standardized criteria linking genetic variants to predicted enzymatic activity and clinical metabolizer phenotype categories.

Phenoconversion and Drug-Drug Interaction Enzymeinduction

Study of medication-induced changes in drug-metabolizing enzyme expression transforming patient metabolizer status during therapy.

Personalized Warfarin Dosing Algorithms and Clinical Utility

Development and validation of pharmacogenetic-guided dosing protocols incorporating CYP2C9 and VKORC1 for anticoagulation management.

Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Investigation of CFTR mutation-specific responses to lumacaftor and ivacaftor highlighting phenotype-dependent therapeutic efficacy patterns.

HER2 Mutation Status in Targeted Cancer Pharmacotherapy

Study of human epidermal growth factor receptor variants predicting response to trastuzumab and other HER2-directed therapeutic agents.

EGFR Mutation Testing for Personalized Lung Cancer Treatment

Analysis of epidermal growth factor receptor mutations guiding selection of tyrosine kinase inhibitor therapy in non-small cell lung cancer.

KRAS Mutations and Cetuximab Resistance in Colorectal Cancer

Investigation of KRAS activating mutations predicting lack of response to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

BRAF V600E Mutations and Melanoma Treatment Response

Study of BRAF mutations determining eligibility for vemurafenib and other targeted therapies in melanoma precision oncology.

PD-L1 Expression Biomarkers and Immunotherapy Response Prediction

Investigation of programmed death ligand expression levels predicting checkpoint inhibitor efficacy in cancer immunotherapy applications.

Pharmacogenetics of Psychotropic Drug Response and Side Effects

Study of genetic variants in serotonin transporters and dopamine receptors predicting antidepressant and antipsychotic medication response.

CYP2C19 and Citalopram-Escitalopram Dosing Recommendations

Investigation of FDA-approved pharmacogenetic dosing guidelines for serotonin reuptake inhibitors based on CYP2C19 metabolizer status.

Lithium Pharmacogenetics and Therapeutic Drug Monitoring

Study of genetic factors influencing lithium renal clearance and toxicity risk in bipolar disorder long-term maintenance therapy.

Solute Carrier Transporter Gene Polymorphisms and Drug Uptake

Characterization of SLC-family transporter variants controlling cellular drug entry and intracellular concentration affecting treatment efficacy.

ABC Transporter Gene Variants and Efflux-Mediated Resistance

Investigation of ATP-binding cassette transporter polymorphisms modulating drug efflux and contributing to multidrug resistance phenomena.

Vitamin K Epoxide Reductase Complex Warfarin Interaction

Study of VKORC1 gene variants affecting vitamin K cycling and establishing baseline warfarin requirement for stable anticoagulation.

Pharmacogenetic Testing Implementation in Clinical Practice

Evaluation of clinical utility, cost-effectiveness, and adoption strategies for pharmacogenetic testing in routine medical care.

Electronic Health Record Integration of Pharmacogenetic Data

Development of clinical decision support systems embedding pharmacogenetic information into electronic prescribing and medication management workflows.

Machine Learning Prediction of Drug Response Phenotypes

Application of artificial intelligence and supervised learning algorithms to predict complex drug response phenotypes from multiomics data.

Polygenic Risk Scores for Medication Efficacy Prediction

Development of composite genetic scores aggregating multiple common variants to enhance predictive accuracy for drug response outcomes.

Organoid and In Vitro Models of Pharmacogenetic Prediction

Establishment of patient-derived cellular and tissue models recapitulating individual pharmacogenetic profiles for personalized drug efficacy testing.

Pharmacogenomic Biobanks and Real-World Evidence Generation

Development of large-scale biorepositories linking genomic data with longitudinal clinical outcomes to validate pharmacogenetic associations.

Pregnancy-Related Pharmacogenetics and Fetal Drug Exposure

Investigation of altered drug metabolism during pregnancy and pharmacogenetic variants affecting antepartum and postpartum medication safety.

Pharmacogenetic Biomarkers in Triple-Negative Breast Cancer

Investigation of genetic variants predicting therapeutic response to chemotherapy and immunotherapy in triple-negative breast cancer subtypes.

Long Non-Coding RNA Regulation of Drug Metabolism

Exploration of lncRNA mechanisms controlling expression and activity of cytochrome P450 and phase II metabolizing enzymes.

Mitochondrial DNA Variants and Drug Toxicity Susceptibility

Study of mitochondrial genetic polymorphisms influencing cellular energy metabolism and adverse drug reaction pathways.

TPMT Allelic Variants in Indigenous Populations

Characterization of unique TPMT gene variants in underserved indigenous populations and their thiopurine metabolism implications.

Drug Transporter Saturation and Pharmacokinetic Nonlinearity

Mechanistic modeling of how genetic variation in transporter expression affects dose-dependent pharmacokinetic behavior.

Tumor Microenvironment and Chemotherapy Pharmacogenetics

Investigation of how tumor stromal composition and immune infiltration modulate pharmacogenetic predictors of chemotherapy efficacy.

Phase III Drug Conjugation Enzyme Polymorphisms

Comprehensive analysis of genetic variations in UDP-glucuronosyltransferases, sulfotransferases, and glutathione-S-transferases affecting drug clearance.

Circadian Rhythm Genes and Temporal Drug Response

Examination of clock gene polymorphisms and circadian regulation of metabolic enzyme expression on drug efficacy timing.

Pharmacogenetics of Opioid Receptor Antagonist Response

Genetic profiling of OPRM1 and OPRK1 variants predicting naltrexone and buprenorphine effectiveness in addiction treatment.

Ion Channel Gene Variants and Cardiac Arrhythmia Risk

Analysis of polymorphisms in cardiac potassium and sodium channels predicting drug-induced QT prolongation susceptibility.

Pharmacogenomics of Proton Pump Inhibitor Metabolism

Investigation of CYP2C19 and CYP3A4 polymorphisms affecting omeprazole, lansoprazole, and pantoprazole bioavailability and efficacy.

Gut Microbiota Genetic Variation and Drug Bioactivation

Study of microbial genome polymorphisms encoding metabolizing enzymes that activate or inactivate prodrugs and xenobiotics.

NUDT15 Deficiency and Thiopurine Toxicity Mechanisms

Mechanistic characterization of NUDT15 loss-of-function variants causing thioguanine nucleotide accumulation and hematologic toxicity.

Pharmacogenetic Counseling in Prenatal Care Settings

Development and evaluation of genetic counseling frameworks for medication selection during pregnancy based on maternal and fetal pharmacogenomics.

Proteasome Inhibitor Response and Genetic Polymorphisms

Identification of genetic variants affecting bortezomib, carfilzomib, and ixazomib pharmacokinetics and therapeutic outcomes in multiple myeloma.

Epigenetic Histone Modification and Pharmacogene Silencing

Investigation of DNA methylation and histone acetylation patterns regulating CYP and transporter gene expression in disease states.

Statin-Induced Myopathy Genetic Risk Score Development

Creation and validation of polygenic risk models incorporating SLCO1B1, CYP3A4, and muscle-specific variants for statin intolerance prediction.

Targeted Therapy in ALK-Rearranged Lung Adenocarcinoma

Pharmacogenomic analysis of ALK fusion variants and downstream signaling mutations predicting ALK inhibitor sensitivity and resistance mechanisms.

Immunosuppressant Pharmacogenetics in Organ Transplantation

Comprehensive study of CYP3A5, MDR1, and IMPDH polymorphisms optimizing tacrolimus, cyclosporine, and mycophenolate dosing post-transplant.

Anti-TNF Therapy Response and Host Genetic Predictors

Investigation of TNF-alpha signaling pathway variants predicting infliximab, adalimumab, and etanercept response in inflammatory bowel disease.

Fluoroquinolone Pharmacogenomics and Tendinopathy Risk

Genetic screening for variants in collagen synthesis and matrix metalloproteinase genes predicting fluoroquinolone-induced tendon rupture risk.

RNA Splicing Variants in Pharmacogene Expression

Identification and functional characterization of cryptic splice site mutations and exon-skipping variants affecting drug metabolism enzyme isoforms.

Pharmacogenetics of Tyrosine Kinase Inhibitor Resistance

Analysis of acquired mutations in BCR-ABL and EGFR kinase domains conferring resistance to imatinib and erlotinib therapy.

Maternal Metabolizer Phenotype and Neonatal Drug Exposure

Investigation of maternal CYP2D6 and CYP2C19 phenotypes affecting neonatal exposure to drugs transferred through breast milk.

Antiretroviral Pharmacogenomics in HIV Cure Research

Study of CYP3A5, CYP2B6, and integrase variant associations with long-acting injectable antiretroviral efficacy and durability.

Topoisomerase Inhibitor Sensitivity and Repair Gene Variants

Examination of DNA repair pathway polymorphisms in XPA, ERCC1, and XRCC1 affecting etoposide and irinotecan efficacy.

Pharmacogenetic Data Interoperability and Standards Development

Development and implementation of standardized nomenclature and data exchange formats for clinical pharmacogenetic testing across health systems.

Angiotensin Receptor Blocker Response and Genetic Polymorphisms

Investigation of AGT, ACE, and AGTR1 gene variants predicting losartan, valsartan, and olmesartan blood pressure response heterogeneity.

Post-Transcriptional Modification and Pharmacogene Function

Study of RNA editing and alternative polyadenylation events affecting stability and translation efficiency of cytochrome P450 transcripts.

Checkpoint Inhibitor Efficacy and Tumor Mutational Burden

Investigation of germline pharmacogenetic variants and somatic tumor mutation loads predicting response to PD-1 and CTLA-4 inhibitor immunotherapy.

GABA Receptor Polymorphisms and Benzodiazepine Sensitivity

Characterization of GABRA1, GABRB2, and GABRA2 variants affecting benzodiazepine binding affinity and sedative potency in anxious populations.

Hepatic Fibrosis Progression and Drug Metabolism Decline

Longitudinal study of how genetic predisposition to liver fibrosis alters cytochrome P450 expression and drug clearance capacity.

Antimalarial Drug Resistance and Plasmodium Genomics

Integration of parasite genetic variants in DHFR, DHPS, and pfmdr1 with human pharmacogenomics predicting artemisinin combination therapy efficacy.

Pharmacogenomics of Insulin Secretagogue Hypoglycemia Risk

Genetic profiling of KCNJ11 and ABCC8 variants predicting individual hypoglycemia susceptibility to sulfonylurea and meglitinide therapy.

Three-Dimensional Protein Structure and Drug Binding Kinetics

Computational molecular modeling of how nonsynonymous pharmacogene variants alter protein folding and drug substrate binding affinity.

Glucocorticoid Receptor Polymorphisms and Steroid Responsiveness

Investigation of NR3C1 gene variants determining glucocorticoid sensitivity in inflammatory and autoimmune disease treatment.

Liquid Biopsy Circulating Tumor DNA and Treatment Selection

Development of non-invasive pharmacogenomic approaches using circulating tumor DNA to guide real-time chemotherapy and targeted therapy adjustments.

Serotonin Transporter Variants and Antidepressant Response

Mechanistic investigation of SERT promoter polymorphisms and brain-derived neurotrophic factor variants in SSRI treatment response prediction.

Vancomycin Nephrotoxicity and Kidney-Specific Gene Variants

Identification of renal transporter and aquaporin polymorphisms conferring susceptibility to vancomycin-induced acute kidney injury.

Platinum Chemotherapy Ototoxicity and Auditory Pathway Genes

Pharmacogenomic screening for variants in mitochondrial 12S rRNA and nuclear cochlear genes predicting cisplatin-induced hearing loss.

Spatial Transcriptomics and Tissue-Specific Drug Metabolism

High-resolution mapping of pharmacogene expression heterogeneity across hepatic zones and extrahepatic tissues using spatial genomics.

Pharmacogenetics in Rare Genetic Disorder Drug Development

Application of pharmacogenomic principles to gene therapy and enzyme replacement therapy dosing in lysosomal and mitochondrial disorders.

Biofilm Formation Genetics and Antibiotic Pharmacokinetics

Investigation of pathogen genetic factors controlling biofilm formation and their interaction with host pharmacogenetics affecting infection clearance.

Dosage Compensation and X-Linked Pharmacogene Expression

Study of X-inactivation patterns and escape from dosage compensation affecting CYP2D6 and other X-chromosome drug metabolism gene expression.

Stochastic Gene Expression Noise and Drug Response Variability

Mathematical modeling of pharmacogene expression fluctuations and single-cell variability in drug response heterogeneity within genetically identical populations.

Pharmacogenomics of SGLT2 Inhibitor Diabetic Ketoacidosis

Genetic screening for variants in glucose metabolism and ketone metabolism pathways predicting euglycemic diabetic ketoacidosis risk with SGLT2 inhibitors.

Environmental Gene-Environment Interactions in Drug Response

Assessment of how pollution exposure, diet, and smoking modify pharmacogenetic risk scores and medication efficacy in diverse populations.

Anaphylaxis Susceptibility Genes and Drug Allergy Cross-Reactivity

Characterization of TSLP, IL-33, and mast cell receptor variants predicting IgE-mediated hypersensitivity reactions to structurally similar antibiotics.

NAT2 Acetylator Phenotype and Drug Toxicity

Investigation of N-acetyltransferase 2 genetic variants and their role in determining acetylation capacity for drugs including sulfonamides, hydralazine, and procainamide toxicity prediction.

TPMT Activity Prediction in Immunosuppressive Therapy

Research on thiopurine methyltransferase genotype-phenotype relationships for optimizing azathioprine and 6-mercaptopurine dosing in autoimmune disease management.

CYP2C9 Warfarin Interactions and Bleeding Risk

Study of cytochrome P450 2C9 polymorphisms combined with VKORC1 variants to predict warfarin dose requirements and hemorrhagic complications.

UGT1A1 Polymorphisms and Irinotecan Toxicity

Examination of UDP-glucuronosyltransferase 1A1 genotype variants influencing irinotecan metabolism and neutropenia risk in colorectal cancer patients.

TPMT and Mercaptopurine Acute Leukemia Treatment

Investigation of thiopurine methyltransferase genotypes guiding personalized mercaptopurine dosing during acute lymphoblastic leukemia maintenance chemotherapy.

CYP2D6 Phenoconversion via Drug Interactions

Research on how CYP2D6 enzyme inhibitors alter metabolizer phenotypes and create clinically relevant drug-drug interactions in psychiatric populations.

OPRM1 Genetic Variants and Opioid Response

Study of mu-opioid receptor gene polymorphisms predicting analgesia efficacy and addiction susceptibility in pain management pharmacotherapy.

COMT Val158Met and Catecholamine Drug Response

Examination of catechol-O-methyltransferase variant effects on dopamine and norepinephrine metabolism influencing psychostimulant and antidepressant responses.

PNMT and Epinephrine Metabolism Polymorphisms

Investigation of phenylethanolamine N-methyltransferase genetic variants affecting adrenergic drug metabolism and cardiovascular medication efficacy.

MTHFR and Methotrexate Efficacy Prediction

Research on methylenetetrahydrofolate reductase C677T and A1298C polymorphisms influencing methotrexate toxicity and therapeutic response in rheumatoid arthritis.

TPMT, NUDT15 and Thiopurine Combination Screening

Study of dual genetic screening combining thiopurine methyltransferase and nudix hydrolase 15 variants for comprehensive leukemia treatment safety assessment.

CYP3A4 Induction and Oral Contraceptive Failure

Investigation of CYP3A4 polymorphisms and inductive interactions with antiepileptic drugs affecting oral contraceptive bioavailability and contraceptive efficacy.

NAT1 and NAT2 Substrate-Dependent Metabolism

Research on both N-acetyltransferase isoforms and their overlapping substrate specificity in predicting drug and xenobiotic acetylation patterns.

SULT1A1 and Minoxidil Hair Growth Response

Examination of sulfotransferase 1A1 variants affecting minoxidil bioactivation and efficacy in androgenetic alopecia pharmacotherapy.

XDH and Allopurinol Metabolism Pharmacogenetics

Study of xanthine dehydrogenase genetic variants influencing allopurinol metabolism and severe cutaneous adverse reaction susceptibility.

PON1 Paraoxonase and Organophosphate Drug Toxicity

Investigation of paraoxonase 1 genetic polymorphisms predicting metabolism of organophosphate compounds and pesticide exposure sensitivity.

GSTM1 Glutathione S-Transferase Null Variants

Research on glutathione S-transferase M1 null genotypes affecting chemotherapy drug detoxification and cancer treatment toxicity risk.

GSTP1 Polymorphisms and Chemotherapy Response

Study of glutathione S-transferase P1 Ile105Val variant influence on platinum-based chemotherapy efficacy and nephrotoxicity prediction.

GSTTZ1 and Doxorubicin-Induced Cardiomyopathy

Examination of glutathione S-transferase zeta 1 genotypes predicting anthracycline cardiotoxicity risk in childhood cancer survivors.

CYP2B6 Efavirenz Pharmacokinetics and CNS Toxicity

Investigation of cytochrome P450 2B6 polymorphisms affecting efavirenz metabolism and neuropsychiatric adverse effects in HIV treatment.

CYP2C8 and Rosiglitazone Hepatotoxicity Risk

Research on cytochrome P450 2C8 variants influencing rosiglitazone bioactivation and hepatic injury susceptibility in diabetic patients.

CYP1A2 and Theophylline Toxicity Prediction

Study of cytochrome P450 1A2 genetic polymorphisms affecting theophylline metabolism and arrhythmia risk in asthma management.

CYP2E1 and Acetaminophen Hepatotoxicity Susceptibility

Examination of cytochrome P450 2E1 polymorphisms predicting N-acetyl-p-benzoquinone imine formation and acetaminophen-induced liver injury risk.

SLCO1B1 and Pravastatin Myopathy Biomarkers

Investigation of organic anion transporting polypeptide 1B1 variants associated with pravastatin muscle toxicity and statin-induced myopathy.

SLCO1B1 and Rosuvastatin Plasma Concentration

Research on solute carrier organic anion transporter 1B1 polymorphisms determining rosuvastatin bioavailability and lipid-lowering efficacy.

SLCO2B1 Substrate Specificity and Drug Uptake

Study of solute carrier organic anion transporter 2B1 variants affecting substrate specificity and tissue penetration of multiple medications.

OCT2 and Metformin Renal Accumulation

Examination of organic cation transporter 2 polymorphisms influencing metformin renal tubular secretion and lactic acidosis risk.

MATE1 and Cimetidine Drug Interactions

Investigation of multidrug and toxin extrusion protein 1 variants affecting cimetidine-mediated organic cation transporter inhibition and drug interactions.

MDR1 and P-glycoprotein Substrate Transport

Research on multidrug resistance protein 1 C3435T polymorphism effects on P-glycoprotein-mediated drug efflux and bioavailability variation.

BCRP and Mitoxantrone Transporter Polymorphisms

Study of breast cancer resistance protein genetic variants influencing mitoxantrone and topotecan efflux in chemotherapy resistance.

PMAT and Cation Drug Transport Variants

Examination of plasma membrane monoamine transporter polymorphisms affecting dopamine and serotonin medication distribution and efficacy.

Aromatase Inhibitor Metabolism and CYP19A1

Investigation of cytochrome P450 aromatase genetic variants influencing estrogen suppression efficacy in postmenopausal breast cancer treatment.

5-Lipoxygenase Inhibitor Response Pharmacogenetics

Research on leukotriene pathway gene variants predicting zileuton efficacy and asthma control in individual patients.

Angiotensin Converting Enzyme Inhibitor Response

Study of ACE insertion-deletion polymorphism and bradykinin metabolism variants affecting ACE inhibitor efficacy in hypertension treatment.

Bradykinin B2 Receptor Variants and ACE Cough

Examination of bradykinin receptor polymorphisms predicting ACE inhibitor-induced persistent cough side effect susceptibility.

Beta-Adrenergic Receptor Polymorphisms and Response

Investigation of beta-1 and beta-2 adrenergic receptor variants affecting beta-blocker efficacy and heart failure treatment response.

Angiotensinogen and Losartan Efficacy Prediction

Research on angiotensinogen M235T variant influence on angiotensin II receptor antagonist blood pressure lowering efficacy.

CYP11B2 and Aldosterone Antagonist Response

Study of cytochrome P450 11B2 polymorphisms predicting spironolactone and eplerenone efficacy in heart failure and hypertension.

HLA-B*1502 and Phenytoin Severe Reactions

Examination of HLA-B*1502 allele frequency across Asian populations and association with Stevens-Johnson syndrome risk in antiepileptic therapy.

HLA-A*3101 and Carbamazepine Hypersensitivity

Investigation of HLA-A*3101 genotyping for predicting carbamazepine-induced hypersensitivity reactions across diverse ethnic populations.

HLA-DRB1 and Flucloxacillin Hepatotoxicity

Research on HLA-DRB1 and HLA-DQA1 variants associated with flucloxacillin-induced liver injury and drug-induced immune hepatitis.

CYP2D6 Zygosity and Metabolizer Class Prediction

Study of cytochrome P450 2D6 allelic combinations and gene deletion events determining ultra-rapid, rapid, normal, and poor metabolizer phenotypes.

CYP2D6 Gene Duplication and Ultrarapid Metabolism

Examination of CYP2D6 gene amplification causing ultra-rapid drug metabolism and therapeutic failure in codeine and tramadol analgesia.

CYP2D6 Hybrid Genes and Functional Variants

Investigation of CYP2D6-CYP2D7 hybrid gene structures and their impact on enzyme function and antipsychotic drug metabolism.

Digoxin Pharmacogenetics and MDR1 Transporter

Research on multidrug resistance protein 1 and CYP3A4 variants affecting digoxin bioavailability and cardiac glycoside toxicity risk.

Dabigatran Metabolism and OATP1B1 Variants

Study of organic anion transporting polypeptide 1B1 polymorphisms influencing dabigatran bioavailability and anticoagulation efficacy.

Apixaban Pharmacogenomics and CYP3A5

Examination of CYP3A5 and CYP3A4 genetic variation affecting apixaban metabolism and bleeding risk in anticoagulation therapy.

Rivaroxaban Bioavailability and Transporter Variants

Investigation of organic anion transporter and P-glycoprotein variants predicting rivaroxaban plasma concentrations and thrombotic complications.

POR Cytochrome P450 Reductase Polymorphisms

Research on P450 oxidoreductase genetic variants affecting multiple CYP enzyme activities and drug metabolism capacity globally.

Rare Pharmacogenetic Variants and Exome Sequencing

Study of ultra-rare coding variants in drug metabolism genes identified through whole exome sequencing in adverse drug reaction cases.

NUDT15 Variants in Thiopurine Metabolism and Leukemia

Investigation of NUDT15 genetic polymorphisms and their role in thiopurine drug metabolism, toxicity prediction, and optimized dosing in pediatric acute lymphoblastic leukemia treatment.

NAT2 Acetylator Status in Tuberculosis Drug Efficacy

Study of N-acetyltransferase 2 phenotypes and their impact on tuberculosis treatment outcomes, particularly with rifampicin and isoniazid combinations.

TPMT Allelic Diversity and Immunosuppressive Drug Safety

Comprehensive analysis of TPMT genetic variants across diverse populations and their prediction of thiopurine-induced myelotoxicity in transplantation and autoimmune disease contexts.

CYP2C9 Variants and NSAID-Induced Gastric Ulceration

Investigation of cytochrome P450 2C9 polymorphisms as predictive biomarkers for non-steroidal anti-inflammatory drug-related gastrointestinal adverse events.

GSTM1 Deletion and Chemotherapy Toxicity Susceptibility

Examination of glutathione S-transferase M1 null variants and their association with increased cancer chemotherapy-induced toxicity and treatment discontinuation rates.

SLC22A2 Polymorphisms in Metformin Accumulation Risk

Study of organic cation transporter 2 genetic variations affecting metformin bioavailability, renal clearance, and lactic acidosis risk in diabetic patients.

IFNL3 Genotype Prediction in Hepatitis C Antiviral Response

Analysis of interferon lambda 3 genetic variants as prognostic markers for sustained virologic response to direct-acting antiviral therapy in hepatitis C infection.

IL28B Polymorphisms and Pegylated Interferon Treatment Outcomes

Investigation of interleukin 28B genetic variants predicting treatment response and adverse effects in hepatitis C patients receiving pegylated interferon-alpha-based regimens.

CYP3A7 Expression in Pediatric Drug Metabolism Ontogeny

Exploration of fetal and neonatal CYP3A7 expression patterns and genetic regulation affecting drug clearance capacity and safe dosing in pediatric populations.

OPRM1 Mu-Opioid Receptor Variants and Analgesic Efficacy

Study of functional mu-opioid receptor genetic polymorphisms determining inter-individual variability in opioid analgesia potency and addiction susceptibility.

COMT Val158Met Polymorphism in Psychotropic Drug Response

Investigation of catechol-O-methyltransferase functional variants and their influence on antipsychotic and antidepressant medication efficacy and side-effect profiles.

Brain-Derived Neurotrophic Factor Variants in Antidepressant Response

Analysis of brain-derived neurotrophic factor genetic polymorphisms as predictive biomarkers for selective serotonin reuptake inhibitor treatment response in major depression.

MTHFR Polymorphisms in Methotrexate Toxicity Prediction

Comprehensive examination of methylenetetrahydrofolate reductase variants and their association with methotrexate-induced hematologic and hepatic toxicity in cancer and autoimmune patients.

ADORA2A Caffeine Sensitivity and CYP1A2 Interaction

Study of adenosine A2A receptor genetic variants influencing caffeine sensitivity and drug-drug interaction potential with CYP1A2-metabolized medications.

CYP2D6 Gene Duplication and Codeine Toxicity in Children

Investigation of CYP2D6 copy number duplications causing ultra-rapid metabolizer phenotype and opioid toxicity risk in pediatric cough and pain management.

VKORC1 and CYP2C9 Integrated Warfarin Dosing Algorithms

Development and validation of combined genotype-based warfarin dosing models incorporating vitamin K oxidoreductase and cytochrome P450 variants for improved anticoagulation control.

HLA-B*1502 Screening in Carbamazepine-Induced SJS-TEN

Examination of human leukocyte antigen B*1502 allele prevalence in Asian populations and implementation of pre-treatment genetic screening to prevent carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.

CYP2B6 Variants in HIV Protease Inhibitor Metabolism

Study of cytochrome P450 2B6 polymorphisms affecting ritonavir boosting efficacy, drug-drug interactions, and virologic outcomes in antiretroviral therapy regimens.

G6PD Deficiency Variants and Antimalarial Drug Safety

Investigation of glucose-6-phosphate dehydrogenase genetic variants determining primaquine and chloroquine safety profiles and hemolytic anemia risk in malaria treatment.

Dihydropyrimidine Dehydrogenase Variants and 5-FU Toxicity

Comprehensive analysis of DPYD gene polymorphisms causing fluorouracil pharmacokinetic alterations and prediction of severe myelosuppression and gastrointestinal toxicity.

SLCO1B1 Variants and Rosuvastatin-Induced Myopathy Risk

Study of solute carrier organic anion transporter family member 1B1 polymorphisms affecting rosuvastatin hepatic uptake and muscle injury susceptibility in statin therapy.

CYP1A2 Polymorphisms in Theophylline Therapeutic Drug Monitoring

Investigation of cytochrome P450 1A2 genetic variants influencing theophylline clearance and the utility of therapeutic drug monitoring in pediatric asthma management.

UGT1A1 Variants in Irinotecan Glucuronidation and Toxicity

Analysis of UDP-glucuronosyltransferase 1A1 polymorphisms, particularly the TA repeat expansion, predicting irinotecan-induced neutropenia and diarrhea in colorectal cancer chemotherapy.

TPMT Phenotyping Methods and Genotype-Phenotype Discordance

Comparative evaluation of TPMT activity measurement techniques and investigation of cases where genetic genotype does not predict functional enzyme phenotype.

Mitochondrial DNA Variants in Drug-Induced Lactic Acidosis

Study of mitochondrial genome polymorphisms and heteroplasmy affecting mitochondrial function and susceptibility to nucleoside reverse transcriptase inhibitor-induced lactate accumulation.

CYP2C19 Loss-of-Function Variants in Proton Pump Inhibitors

Investigation of cytochrome P450 2C19 genotype-dependent metabolism of omeprazole and pantoprazole affecting Helicobacter pylori eradication rates and acid suppression efficacy.

APOE Genotype and Statin-Induced Cognitive Changes

Examination of apolipoprotein E polymorphisms as genetic risk factors modifying statin-associated muscle pain and cognitive side effects reported by patients.

GSTM1 and GSTT1 Null Variants in Acetaminophen Hepatotoxicity

Analysis of glutathione S-transferase M1 and T1 deletion variants affecting acetaminophen detoxification capacity and susceptibility to overdose-induced liver failure.

LDLR Mutations in Statin Response and Familial Hypercholesterolemia

Study of low-density lipoprotein receptor genetic defects determining statin efficacy stratification and need for advanced lipid-lowering therapies in familial hypercholesterolemia.

Ethnicity-Specific CYP2D6 Allele Frequencies and Drug Metabolism

Investigation of population-specific CYP2D6 variant distributions across African, Asian, European, and Hispanic populations and implications for personalized antidepressant dosing.

PON1 Polymorphisms in Statin and Arylesterase Activity

Study of paraoxonase 1 genetic variants affecting enzyme activity, antioxidant function, and cardiovascular outcomes in patients receiving statin therapy.

CYP4F2 Variants in Vitamin K-Dependent Coagulation Control

Investigation of cytochrome P450 4F2 polymorphisms affecting vitamin K oxidation and their contribution to warfarin dose variability independent of VKORC1 and CYP2C9 genotypes.

ADORA2A Genotype and Caffeine-Induced Anxiety Disorders

Examination of adenosine A2A receptor genetic variants determining caffeine sensitivity, anxiety response, and psychiatric symptom exacerbation in vulnerable populations.

SLC6A4 Serotonin Transporter Polymorphisms and SSRI Response

Study of serotonin transporter promoter region polymorphisms predicting selective serotonin reuptake inhibitor treatment response and time to therapeutic effect in depression.

HLA-B*5701 Screening Protocol Optimization in HIV Treatment

Development of efficient and cost-effective HLA-B*5701 genotyping strategies for abacavir hypersensitivity prevention in resource-limited and developed healthcare settings.

N-Acetyltransferase 1 Variants in Doxorubicin Cardiotoxicity

Investigation of NAT1 polymorphisms affecting acetylation of doxorubicin metabolites and predicting cardiac toxicity risk in breast cancer chemotherapy recipients.

CYP19A1 Variants in Aromatase Inhibitor Response Prediction

Study of cytochrome P450 19A1 genetic polymorphisms affecting aromatase enzyme activity and estrogen suppression efficacy in hormone receptor-positive breast cancer patients.

TGFB1 Variants in Chemotherapy-Induced Pulmonary Fibrosis

Examination of transforming growth factor-beta 1 genetic polymorphisms as risk factors for bleomycin and taxane-induced pulmonary fibrosis development during cancer treatment.

UGT2B7 Variants in Morphine Glucuronidation and Efficacy

Investigation of UDP-glucuronosyltransferase 2B7 polymorphisms affecting morphine metabolism, analgesic potency, and active metabolite accumulation in chronic pain management.

CYP11B2 Polymorphisms in Aldosterone Synthase Activity

Study of cytochrome P450 11B2 genetic variants affecting aldosterone production and hypertension susceptibility in patients receiving mineralocorticoid receptor antagonist therapy.

CRHR1 Stress Receptor Variants in Antidepressant Treatment Response

Analysis of corticotropin-releasing hormone receptor 1 genetic polymorphisms modifying stress response pathways and predicting antidepressant treatment outcomes in major depression.

Human Platelet Antigen Diversity in Drug Immunogenicity

Investigation of human platelet antigen genetic polymorphisms affecting heparin-induced thrombocytopenia and quinine-induced immune thrombocytopenia pathogenesis and severity.

GRIN2B N-Methyl-D-Aspartate Receptor Variants in Anesthesia

Study of glutamate ionotropic receptor NMDA type subunit 2B genetic polymorphisms affecting ketamine metabolism and anesthetic response variability in surgical populations.

CYP2A6 Variants in Nicotine Metabolism and Smoking Cessation

Investigation of cytochrome P450 2A6 polymorphisms affecting nicotine clearance rates and response to nicotine replacement therapy and varenicline in smoking cessation interventions.

GSTM3 Variants in Chemotherapy and Environmental Toxin Exposure

Examination of glutathione S-transferase M3 genetic polymorphisms affecting detoxification of chemotherapy agents and cumulative exposure to environmental carcinogens.

Rare Genetic Variants in Orphan Pharmacogenetics Populations

Discovery and functional characterization of uncommon and novel CYP and transporter gene variants in underrepresented populations through whole genome sequencing approaches.

Polygenic Risk Scores for Medication Adverse Event Prediction

Development and validation of weighted polygenic risk score models integrating multiple common variants to predict individual susceptibility to drug-induced adverse events.

CRISPR-Cas9 Gene Editing Models for Drug Metabolism Testing

Application of genome editing technology to create cellular models with specific pharmacogenetic variants for in vitro drug metabolism and toxicity prediction studies.

Intestinal Microbiota Dysbiosis and Drug Metabolism Alterations

Investigation of how gut microbiome composition changes affect bacterial enzyme activity and bioavailability of drugs metabolized by intestinal flora.

Pharmacogenomic Biobank Data Mining for Real-World Outcomes

Large-scale computational analysis of integrated biobanks with genetic and clinical data to identify novel pharmacogenetic associations and treatment response patterns.

Pharmacogenetic Interactions in Polypharmacy Management

Investigation of genetic-based drug-drug interactions and cumulative metabolic burden in patients on multiple medications requiring personalized dosing optimization.

Non-coding RNA Variants and Drug Response Modulation

Exploration of how polymorphisms in regulatory RNA elements including long non-coding RNA and small nucleolar RNA influence pharmacogene expression and therapeutic outcomes.